paclitaxel

Angioplasty using a drug eluting balloon in the superficial femoral artery

Original title:&nbsp;Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial.&nbsp;Reference:&nbsp;Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or<a href="https://solaci.org/en/2015/04/27/angioplasty-using-a-drug-eluting-balloon-in-the-superficial-femoral-artery/" title="Read more" >...</a>

Risks and benefits of Dual Antiplatelet beyond the year of a drug-eluting stent

Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents.&nbsp;Reference: Laura Mauri et al. N Engl J Med 2014;371:2155-66. &nbsp; Dual antiplatelet therapy is recommended after a drug-eluting stent to prevent thrombotic complications. The clinical benefit of this scheme it is not clear beyond one year. Patients were registered to receive a<a href="https://solaci.org/en/2015/01/13/risks-and-benefits-of-dual-antiplatelet-beyond-the-year-of-a-drug-eluting-stent/" title="Read more" >...</a>

Superficial Femoral Artery In-Stent Restenosis with Drug Eluting Balloon: 2 Year Follow Up.

Original title:&nbsp;Drug-Eluting Balloons for the Treatment of the Superficial Femoral Artery In-Stent Restenosis. 2-Year Follow-Up.&nbsp;Reference:&nbsp;Vittorio Virga et al. J Am Coll Cardiol Intv 2014;7:411&ndash;5. Although the use of the self-expanding nitinol stent has improved angioplasty outcomes in femoropopliteal territory, restenosis remains a challenge still affecting at least 25% of the population in the first year.<a href="https://solaci.org/en/2014/07/08/superficial-femoral-artery-in-stent-restenosis-with-drug-eluting-balloon-2-year-follow-up/" title="Read more" >...</a>

SYNTAX study final monitoring at 5-years

Original title:&nbsp;Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.&nbsp;Reference:&nbsp;Eur Heart J. 2014 May 21. pii: ehu213. (Epub ahead of print). The SYNTAX study was one of the largest randomized clinical studies comparing long-term results of angioplasty versus surgery in multivessel disease and /or<a href="https://solaci.org/en/2014/07/04/syntax-study-final-monitoring-at-5-years/" title="Read more" >...</a>

3 to 6 months of dual antiplatelet after DES reduced bleeding and did not raise mortality or infarction.

Original title:&nbsp;Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug eluting stents.&nbsp;Reference:&nbsp;El-Hayek G et al. Am J Cardiol. 2014; Epub ahead of print. This meta-analysis examined the data of four randomized and controlled studies (EXCELLENT, PRODIGY, RESET y OPTIMIZE) including 8157 patients receiving sirolimus, paclitaxel, everolimus or zotarolimus<a href="https://solaci.org/en/2014/06/24/3-to-6-months-of-dual-antiplatelet-after-des-reduced-bleeding-and-did-not-raise-mortality-or-infarction/" title="Read more" >...</a>

Cohort with left main coronary injury of SYNTAX. Final monitoring at 5 years.

Original title:&nbsp;Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.&nbsp;Reference: Morice MC et al. Circulation. 2014 Jun 10;129(23):2388-94. &nbsp; Current guidelines recommend CABG as the strategy of choice for treating lesions of<a href="https://solaci.org/en/2014/06/19/cohort-with-left-main-coronary-injury-of-syntax-final-monitoring-at-5-years/" title="Read more" >...</a>

Angioplasty in sirolimus &#8211; eluting stent restenosis is safe and effective beyond the change of drug.

Original title:&nbsp;Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial.&nbsp;Reference:&nbsp;Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75. &nbsp; DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to<a href="https://solaci.org/en/2014/05/06/angioplasty-in-sirolimus-eluting-stent-restenosis-is-safe-and-effective-beyond-the-change-of-drug/" title="Read more" >...</a>

Everolimus-eluting stent and DEB in restenosis for BMS. Good results of both with some expected differences.

Original title:&nbsp;A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial.&nbsp;Reference:&nbsp;Fernando Alfonso et al. J Am Coll Cardiol. 2014; Epub ahead of print. &nbsp; Drug-eluting stents (DES) have proven to be superior in terms of restenosis than bare metal stents (BMS). BMS, however due<a href="https://solaci.org/en/2014/01/22/everolimus-eluting-stent-and-deb-in-restenosis-for-bms-good-results-of-both-with-some-expected-differences/" title="Read more" >...</a>

Everolimus -eluting stent to 3 years, most security was the key difference.

Original title:&nbsp;Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.&nbsp;Reference:&nbsp;Sorin J. Brener et al. Am Heart J 2013;0:1-8. The XIENCE stent (Abbott Vascular, Santa Clara, CA) is<a href="https://solaci.org/en/2013/12/10/everolimus-eluting-stent-to-3-years-most-security-was-the-key-difference/" title="Read more" >...</a>

Drug eluting balloon followed BMS versus DES in de novo lesions

Original title:&nbsp;Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial.&nbsp;Reference:&nbsp;Francesco Liistro et al. Am Heart J 2013;166:920-6. Recently, drug eluting balloons (DEB) have emerged as a potential alternative to drug-eluting stents (DES). Paclitaxel is an appropriate drug for DEBs given<a href="https://solaci.org/en/2013/12/03/drug-eluting-balloon-followed-bms-versus-des-in-de-novo-lesions/" title="Read more" >...</a>

Top